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Abstract—Clinical studies have reported lower eﬀectivity of opioid drugs in therapy of neuropathic pain. There-
fore, to determine the changes in endogenous opioid systems in this pain more precisely, we have studied the
changes in the pain-related behavior on days 1, 14, and 28 following a chronic constriction injury (CCI) to the sci-
atic nerve in mice. In parallel, we have studied the changes of -(MOP), -(DOP) and -(KOP) receptors, proenkephalin
(PENK) and prodynorphin (PDYN) mRNA levels, as well as GTPcS binding of opioid receptors on the ipsi- and con-
tralateral parts of the spinal cord and thalamus on the 14th day following CCI, as on this day the greatest mani-
festation of pain-related behavior was observed. On ipsilateral spinal cord, the decrease in MOP/DOP/KOP
receptor and increase in PDYN/PENK mRNA expression was observed. In thalamus, MOP/DOP/KOP receptor
expression decreased contralaterally. On ipsilateral side, there were no changes in PDYN/PENK or DOP/KOP
receptor expression, but MOP mRNA decreased. The spinal GTPcS binding of MOP/DOP/KOP receptor ligands
decreased on the ipsilateral side, yet the eﬀect was less pronounced for DOP receptor ligands. In thalamus, a
decrease was observed on the contralateral side for all opioid receptor ligands, especially for DOP ligand. A less
pronounced decrease in GTPcS binding of spinal DOP ligands may indicate a weaker stimulation of ascending
nociceptive pathways, which could explain the absence of decreased activity of DOP receptor ligands in neuropa-
thy. These ﬁndings may suggest that drugs with a higher aﬃnity for the DOP receptor will perform better in neu-















Neuropathic pain tends to be less opioid responsive than
nociceptive pain, and opioids are only partially eﬀective in
preclinical models of neuropathic pain, and this
phenomenon is not fully understood. The analgesic
properties of opioid drugs in neuropathic pain may
depend on molecular changes in endogenous opioid
systems that contribute to the development and
maintenance of this type of pain by weaker
counteracting pain stimulation. Any nerve tissue injury
leads to endogenous changes on the molecular and
systemic levels, with antinociceptive systems being
rapidly activated just after injury, and losing their initial
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neuroscience.2018.08.013changes, including intensiﬁed release of pronociceptive
molecules, counteract the action of exogenous opioids;
this, with weakened eﬃcacy of endogenous
antinociceptive systems themselves, contributes to
unsatisfying analgesic eﬀect of opioid drugs, which are
eventually far less eﬃcient in neuropathic pain than in
nociceptive pain. It has been shown in a number of
studies that the activity of endogenous opioid peptides
is changed by nociceptive and chronic painful stimuli;
the increase in endogenous opioid peptide release
consequently enhances opioid receptor occupancy. This
eﬀect has been documented in animal and human
studies (Albe-Fessard et al., 1985; Iadarola et al., 1988;
Zangen et al., 1998; Zubieta et al., 2001; Bencherif
et al., 2002; Obara et al., 2009; Mika et al., 2014;
Popiolek-Barczyk et al., 2014). Neuropathic pain is asso-
ciated with signiﬁcant changes in spinal and thalamic neu-
ronal activity and sensitization of the neural structures
involved in pain perception (Patel and Dickenson, 2016;
Sandkuler et al., 2011), which may play a key role in the
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7 September 2018Changes characteristic of neuropathic pain may also be
induced in animal models (Henderson et al., 2013). Opi-
oid peptides and their receptors are normally involved in
mechanisms blocking out pain, and their functional and
biochemical alterations appear to display a critical role
in the development and maintenance of neuropathic pain.
Our previous studies have shown a decrease in the
expression of opioid receptors in the ipsilateral part of
the spinal cord and DRG in rat and mouse models of
neuropathy (Obara et al., 2009; Mika et al., 2014;
Popiolek-Barczyk et al., 2014). Interestingly, in patients
suﬀering from chronic central pain, a positron-emission
tomography study has shown a decrease in opioid [11C]
diprenorphine binding in the thalamus contralaterally to
the painful side (Maarrawi et al., 2007b). This study was
however, limited only to the MOP receptor; but because
opioids have diﬀerent aﬃnities for opioid receptors, it is
important to know which receptor proﬁle of the opioid drug
is the most suitable for the treatment of neuropathy. And
therefore, studying changes in individual types of opioid
receptors may help indicate such a drug.
An injury of a nervous tissue leads to complex
changes in ascending tracts, from peripheral nervous
system, through spinal cord, to brain structures. Our aim
was to verify whether inﬂicting an injury just on one site
of the nervous system would cause uni- or bilateral
changes, and whether the changes are similar in the
spinal cord and in the brain tracts. That is why we
focused on the issue, as it could potentially explain
some aspects of neuropathic pain development and
opioid drugs action. Recently, asymmetry in diﬀerent
functions in the brain in neuropathic pain has been
suggested (Leite-Almeida et al., 2014), and this problem
needs to be addressed more extensively in animal neuro-
pathic pain models. Obara et al. (2010) demonstrated that
diﬀerences in the pharmacological eﬀectiveness of diﬀer-
ent opioid receptor ligands with peptide and nonpeptide
chemical structures in neuropathic pain could result from
functional changes in the -(MOP) receptor in the spinal
cord and DRG in a chronic constriction injury (CCI) rat
model and Narita et al. (2002) have demonstrated that
nerve injury leads to a decrease in MOP receptor-
mediated G-protein activation in the spinal cord and in
the brain. Little is known, however, about the functional
alterations of KOP and DOP receptors in the nociceptive
pathways upon neuropathic pain. This is of particular
interest, since opioids with particular (diﬀerential) selectiv-
ity for opioid receptor types may be more suited for treat-
ment of neuropathic pain. In our current research we have
used besides MOP-, -(DOP) and -(KOP) mRNA level, the
selective opioid receptor ligand-stimulated guanosine-50-
o-(3-thio) triphosphate (GTPcS) binding to measure the
activation of G-proteins. This method characterizes the
functional state of the receptor and provides convenient
measures of opioid receptor activity close to the receptor
in the signaling cascade. The results presented in this
paper extend earlier observations (Zhang et al., 1998;
Xiao et al., 2008; Obara et al., 2009) and provide addi-
tional impact on our understanding of the mechanisms
of reduced antinociceptive eﬀectiveness of opioids under
neuropathic pain conditions.Please cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic O
neuroscience.2018.08.013Therefore, in the present paper, we analyzed
neuropathic pain-related behavioral changes estimated
1, 14, and 28 days after sciatic nerve injury. In parallel,
we have studied the changes of MOP, DOP and KOP
receptors, proenkephalin (PENK) and prodynorphin
(PDYN) mRNA levels, as well as GTPcS binding of
opioid receptors on the ipsi- and contralateral parts of
the spinal cord and thalamus on the 14th day following




Adult male Albino-Swiss CD-1 mice (Charles River,
Germany; 20–25 g) were used in this study. Animals
were housed in groups of six in cages with sawdust
bedding under a standard 12 h/12 h light/dark cycle
(lights on at 06.00 a.m.); food and water were available
ad libitum. All experiments were carried out according to
the recommendations of International Association for the
Study of Pain (Zimmermann, 1983) and the NIH Guide
for Care and Use of Laboratory Animals and were
approved by the Local Bioethics Committee (Krakow,
Poland, permission numbers 1214/2015).
Chronic constriction injury (CCI)
The CCI model was performed according to Bennett and
Xie (1988). The surgical procedure was performed under
isoﬂurane anesthesia. Brieﬂy, an incision was made
below the right hipbone, parallel to the sciatic nerve.
The sciatic nerve was exposed, and three ligatures (4/0
silk) were tied loosely around the nerve distal to the sciatic
notch with 1-mm spacing, until a brief twitch in the respec-
tive hind limb was observed. After CCI, all mice developed
tactile/thermal hypersensitivity. The mice with sciatic
nerve injury will be referred to by the abbreviation ‘‘CCI
mice” throughout the text of the manuscript. The beha-
vioral experiments were conducted on the 1st, 14th and
28th day following the CCI surgical procedure. Biochemi-
cal experiments were conducted on the 14th day after
injury, the day of major changes in response to thermal
and mechanical stimuli.
Behavioral testsVon Frey’s test. Mechanical tactile hypersensitivity in
CCI mice was measured on the 1st, 14th and 28th day
after CCI using a series of von Frey ﬁlaments (Stoelting,
Wood Dale, IL, USA), ranging from 0.6 to 6 g (Mika
et al., 2015). Animals were placed in plastic cages with
a wire-mesh ﬂoor, allowing them to move freely. They
were allowed to acclimate to this environment for approx-
imately 5–15 min prior to testing. The von Frey ﬁlaments
were applied in ascending order to the midplantar surface
of the both hind paw through the mesh ﬂoor. Each probe
was applied to the foot until it started to bend. The ipsilat-
eral and contralateral paws in CCI mice (or both hind
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7 September 2018value was calculated. The time interval between consec-
utive applications of ﬁlaments was at least 5 s.
Cold plate test. Sensitivity to noxious thermal stimuli
was assessed on the 1st, 14th and 28th day after CCI
using a Cold/Hot Plate Analgesia Meter from Columbus
Instruments. The latency was deﬁned as the amount of
time it took for the hind paw to begin to shake after the
mouse was placed on a cold plate (2 C). In CCI mice,
the injured paw reacted ﬁrst in all cases. The ipsilateral
paw reaction was noted ﬁrst and then the contralateral
paw response was awaited and noted. In naive mice the
reaction of any hind paw was noted. The cut-oﬀ latency











































276qRT-PCR analysis. RNA extraction and comple-
mentary DNA (cDNA) synthesis. On day 14 after CCI,
when the most pronounced changes in response to
thermal and mechanical stimuli were observed, the mice
were decapitated. Immediately after decapitation the
spinal cord was removed using hydraulic pressure and
the brain was dissected from the skull. Tissue was
collected on ice-cold plate. Spinal cord lumbar
fragments (L4–L6) were divided for ipsi- and
contralateral parts. The thalamus was dissected
according to Palkovits and Brownstein (1987). At ﬁrst
the hypothalamus, cerebellum, cortex hippocampus and
mesencephalon tissues were dissected. Finally the thala-
mus was dissected from the rest of remaining tissue and
divided on ipsi- and contralateral parts to the site of sciatic
nerve injury.
Total RNA was extracted according to the method
described by Chomczynski and Sacchi (1987) using TRI-
zol reagent (Invitrogen) as previously described
(Rojewska et al., 2016). The tissue samples were placed
in individual tubes containing the tissue storage reagent
RNA later (Ambion Inc.) and were stored at 70 C for
RNA isolation. For cDNA synthesis, 1000 ng of total
RNA was reverse transcribed using an Omniscript RT
Kit (Qiagen) with oligo(dT) primer (Fermentas) in a total
reaction volume of 20 ll. The cDNA was diluted 1:10 with
H2O, and for each reaction, approximately 50 ng of cDNA
synthesized from the total RNA template was obtained
from each individual animal and used for quantitative
real-time polymerase chain reaction (qRT-PCR). qRT-
PCR was performed using Assay-On-Demand TaqMan
probes (Applied Biosystems, USA) and run on a Real-
Time PCR iCycler (Bio-Rad, Hercules, CA, USA). The
ampliﬁcation eﬃciency for each assay was determined
by running a standard dilution curve. The following Taq-
Man primers were used: rat hypoxanthine guanine phos-
phoribosyltransferase, (Mm03024075_m1; HPRT1),
PDYN (Mm00457573_m1; Pdyn); preproenkephalin
(Mm01212875_m1; Penk); opioid receptor, mu 1
(Mm01188089_m1; Oprm1, MOP); opioid receptor, delta
1 (Mm01180757_m1; Oprd1, DOP); and opioid receptor,
kappa 1 (Mm01230885_m1; Oprk1, KOP). The Hprt
levels did not signiﬁcantly diﬀer across all groups, and
Hprt was, therefore, used as a housekeeping gene controlPlease cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic O
neuroscience.2018.08.013(data not shown). The cycle threshold values were calcu-
lated automatically with the iCycler IQ 3.0 software using
the default parameters. The RNA abundance was calcu-
lated as 2(threshold cycle).
GTPcS functional binding assayChemicals. The highly selective MOP receptor agonist
enkephalin analog Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol
(DAMGO) and the KOP receptor agonist peptide
dynorphin1–13 were obtained from Bachem Holding AG
(Bubendorf, Switzerland). The structurally modiﬁed DOP
receptor-speciﬁc deltorphin II derivative, Ile5,6deltorphin
II (Tyr-D-Ala-Phe-Gly-lle-lle-Gly-NH2) was synthesized
in the Laboratory of Chemical Biology of the Biological
Research Centre (BRC, Szeged, Hungary). Each ligand
was dissolved in tri distilled water and stored in 1 mM
stock solution at 20 C. EGTA, MgCl2  6H2O, NaCl,
Tris–HCl, guanosine 50-diphosphate sodium salt (GDP)
and guanosine 50-O-[c-thio]triphosphate salt (GTPcS)
were purchased from Sigma–Aldrich (Budapest,
Hungary). The radiolabeled GTP analog [35S]GTPcS
(speciﬁc activity: 3.7  1013 Bq/mmol; 1000 Ci/mol) was
obtained from Hartmann Analytic (Braunschweig,
Germany). The Ultima GoldTM MV harmless scintillation
cocktail was purchased from Perkin Elmer.
GTPcS binding. Mouse spinal cord and thalamus for
G-protein binding assays were collected only on day 14
after CCI, when the most pronounced changes in
response to thermal and mechanical stimuli were
observed. The structures were prepared as described
for the mRNA assay in the section above. The crude
membrane fractions of mouse spinal cord and thalamus
were used for [35S]GTPcS binding experiments after
being prepared as described earlier (Sz}ucs et al, 2016).
Brieﬂy, the thawed and ice-cooled spinal cord and thala-
mus were homogenized on ice in ten volume (10 ml buf-
fer/g original tissue) ice-cold TEM buﬀer (50 mM Tris–
HCl, 1 mM EGTA, 5 mM MgCl2, pH 7.4). Protein concen-
trations were determined by the Bradford method
(Bradford, 1976) and were approximately 4–6 mg/ml.
Membrane samples were then aliquoted into the Eppen-
dorf tubes containing between 50 and 60 ml of membrane
suspensions and stored at  80 C until further
processing.
Opioid ligand-stimulated GTPcS functional binding
assay. In GTPcS binding experiments, the GDPc-GTP
exchange of the Gai/o proteins was measured in the
presence of the ligands to determine their potency and
the maximal eﬃcacy of the activated G-proteins. The
functional [35S]GTPcS binding experiments were
performed as previously described (Traynor and
Nahorski, 1995). Brieﬂy, the membrane proteins
(10 mg/ml) were incubated at 30 C for 60 min with [35S]-
GTPcS (20 MBq/0.05 cm3; 0.05 nM) and increasing con-
centrations (1010–105 M) of DAMGO in Tris–EGTA
buﬀer (pH 7.4) containing 30 mM GDP, 1 mM EGTA,
5 mM MgCl2, 100 mM NaCl and 50 mM Tris–HCl in a ﬁnal
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tracted from the total binding. Basal activity (deﬁned as
100%) indicates constitutive G-protein activity levels in
the absence of any stimulating ligand. Bound and free
[35S]GTPcS were separated by vacuum (Brandel M24R
Cell Harvester) ﬁltration through the Whatman GF/B glass
ﬁber ﬁlters and washed three times with 5 ml of ice-cold
50 mM Tris–HCl (pH 7.4) buﬀer. The analyses were per-
formed in triplicate and repeated at least three times.
Increasing concentrations of the ligands produced
dose-dependent stimulation of [35S]GTPcS binding in
each sample. High activation of G-proteins in MOP
(DAMGO) and KOP (dynorphin1–13) receptors were
observed in the spinal cord and thalamus of naive
animals on both the contralateral and ipsilateral sides.
Moderate stimulations by Ile5,6deltorphin II were found in











Fig. 1. The level of mechanical (A; von Frey test) and thermal (B;
cold plate test) hypersensitivity measured in naı¨ve (N) and 1, 14 and
28 days after injury in CCI mice. The data are presented as mean
± S.E.M. (9–15 mice per group). Intergroup diﬀerences were
analyzed using Bonferroni’s multiple comparison tests. ***p< 0.001
indicates a signiﬁcant diﬀerence compared with the control (naive)
animals; ooop< 0.001 indicates a signiﬁcant diﬀerence compared
with the contralateral side on the respective day after CCI.Data analysis
The behavioral data are presented as mean ± S.E.M. of
9–15 mice per group. Inter-group diﬀerences were
analyzed by ANOVA followed Bonferroni’s multiple
comparison test. Signiﬁcance was deﬁned as
***p< 0.001 indicating a signiﬁcant diﬀerence compared
with the control (naive) animals; ooop< 0.001 indicating
a signiﬁcant diﬀerence compared with the contralateral
side.
The qRT-PCR data are presented as the fold change
of the controls, which represents normalized averages
derived from the threshold cycles in qPCR and from 4 to
10 samples per group. Inter-group diﬀerences were
analyzed by Bonferroni’s multiple comparison test.
Signiﬁcance was deﬁned as *p< 0.05, **p< 0.01
indicating a signiﬁcant diﬀerence compared with the
control (naive) animals. All graphs were prepared using
GraphPad Prism 7.0.
Data analysis of GTPcS binding was performed with
GraphPad Prism 5.0 software (GraphPad Prism
Software Inc., San Diego, CA, USA). Non-linear
regression analysis of the ligand-stimulated [35S]GTPcS
binding assays used the ‘sigmoidal dose–response’
ﬁtting to determine the maximal stimulation or eﬃcacy
(Emax) of the receptors’ G-protein and ligand potency
(EC50). Stimulation is represented as a percent of the
speciﬁc [35S]GTPcS binding observed above the basal
activity level (taken to be 100%). Unpaired t-tests with
two-tailed P-values were performed to determine









Time-course changes in sensitivity to mechanical
and thermal stimuli as measured in naı¨ve mice and 1,
14 and 28 days after injury in CCI mice
Pain thresholds in response to mechanical and thermal
stimuli were measured by the von Frey and cold plate
tests, respectively. No changes in the response to both
types of stimuli were observed on the contralateral paw
at the time points examined (Fig. 1A, B) as compared toPlease cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic O
neuroscience.2018.08.013naı¨ve mice. In contrast, response times on the
ipsilateral side of the injury were signiﬁcantly reduced
starting from the very ﬁrst day after CCI. The lowest
pain threshold in the von Frey test was observed on day
14. On day 28, the threshold reached values closest to
the level of controls, although there was still an
observable signiﬁcant decrease in the pain threshold
(Fig. 1A). The response time to thermal stimuli was also
signiﬁcantly reduced at all measured time points.
Diﬀerences between time points were not large, yet the
strongest eﬀect was observed on day 14 after nerve
injury (Fig. 1B).The level of opioid receptors’ mRNA in the spinal
cord and thalamus measured in naı¨ve mice and
14 days after injury in CCI mice
The levels of MOP, DOP and KOP opioid receptor mRNA
in the spinal cord in CCI mice were not changed on the
contralateral side in comparison with naı¨ve mice. On the







































































Fig. 2. qRT-PCR analysis of the MOP DOP and KOP mRNA levels in the both sides in naı¨ve mice (N)
and ipsi- and contralateral parts of the spinal cord (A–C) and thalamus (D–F) 14 days after injury in
CCI mice. The data are presented as mean ± S.E.M., which represent normalized averages derived
from the threshold cycles obtained from qRT-PCR of 4–8 samples per group. *p< 0.05, **p< 0.01
and ***p< 0.001 indicates a signiﬁcant diﬀerence compared with the naive animals.
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7 September 2018receptors signiﬁcantly decreased in the spinal cord
(Fig. 2A–C). The level of MOP, DOP and KOP receptor
mRNA in the thalamus was reduced signiﬁcantly on the
contralateral side in comparison with naı¨ve mice. On the
ipsilateral side of the thalamus, only mRNA of MOP
receptor decreased (Fig. 2D). The levels of mRNA for
the DOP and KOP receptors did not change on the
ipsilateral side (Fig. 2E, F).Please cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic
neuroscience.2018.08.013The level of PDYN and (PENK
mRNA in the spinal cord and
thalamus measured in naı¨ve
mice and 14 days after injury in
CCI mice
No changes in PDYN and PENK
mRNA levels were observed in
the contralateral part of the spinal
cord; in contrast the levels for
both PDYN and PENK mRNA in
ipsilateral part of the spinal cord
were signiﬁcantly elevated
(Fig. 3A, B). PDYN and PENK
mRNA levels were not
signiﬁcantly altered in either the
contra- or ipsilateral side of the
thalamus (Fig. 3C, D).Dose-dependent stimulation of
GTPcS binding produced by
selective ligands of opioid
receptors in the spinal cord and
thalamus measured in naı¨ve
mice and 14 days after injury in
CCI mice
The observed decreases in
maximal stimulation (Emax) values
in membranes prepared from
naive animals were not signiﬁcant
in any case. The samples from
CCI-exposed mice showed a
diﬀerence in G-protein activity
when comparing contra- and
ipsilateral sides. The maximal
stimulation was signiﬁcantly lower
on the ipsilateral side in the spinal
cord, while a decrease was
observed on the contralateral side
in the thalamus for all three types
of opioid receptors (Table 1).
Signiﬁcant diﬀerences between
contra- and ipsilateral sides were
found in CCI-exposed mice for
MOP receptors in the spinal cord
(***P= 0.0007; two-tailed P-value,
t= 9.594, df = 4) and in the
thalamus (**P= 0.0019; two-tailed
P-value, t= 7.306, df = 4). A
signiﬁcant diﬀerence in G-protein
activation was observed when
comparing the contralateral and
ipsilateral sides of CCI-exposedanimals for DOP receptors in the spinal cord
(**P= 0.0031; two-tailed P-value, t= 6.402, df = 4)
and in the thalamus (*P= 0.0228; two-tailed P-value,
t= 3.598, df = 4). The eﬀect was statistically signiﬁcant
between the contralateral and ipsilateral sides of the

















































Fig. 3. qRT-PCR analysis of the PDYN (A, C) and PENK (B, D) mRNA levels in naı¨ve mice (N) and in
the ipsi- and contralateral spinal cord (A, B) and thalamus (C, D) 14 days after injury in CCI mice. The
data are presented as mean ± S.E.M., which represent normalized averages derived from the
threshold cycles obtained from qRT-PCR of 6–10 samples per group. *p< 0.05, **p< 0.01 indicates
a signiﬁcant diﬀerence compared with the naı¨ve animals.
Table 1. G-protein activation by the selective opioid peptide receptor agonists DAMGO, Ile5,6deltorphin
thalamic membrane preparations of naive and CCI mice on the contra- and ipsilateral sides
Maximal stimulation (eﬃcacy)  Emax ± S.E.M. (%)
Receptor Spinal cord Th
Contra Ipsi Co
MOP Naive 147.5 ± 2.8 144.4 ± 2.1NS 15
CCI 137.0 ± 2.1 113.1 ± 1.3*** 12
DOP Naive 117.3 ± 2.1 114.4 ± 1.0NS 12
CCI 116.1 ± 1.7 104.4 ± 0.6** 11
KOP Naive 146.1 ± 1.6 141.6 ± 3.6NS 14
CCI 146.2 ± 1.0 125.2 ± 2.3 ** 12
Experimental data were processed by GraphPad Prism 5.0 using the sigmoid ﬁt option of the dose–response curve
***p< 0.001 based on unpaired t-tests.
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(**P= 0.0011; two-tailed P-value,
t= 8.362, df = 4) in CCI-exposed
mice for KOP receptors (Table 1).
The GTPcS binding stimulated
by DAMGO, selective peptide
agonist of the MOP-receptor, was
similar in naı¨ve mice (both parts)
and the contralateral part of the
spinal cord in CCI-subjected mice,
yet it was much weaker on the
ipsilateral part of CCI-subjected
mice (Fig. 4A). The GTPcS
binding stimulated by
Ile5,6deltorphin II was very low but
similar between both parts in
naı¨ve mice and contra part of the
spinal cord in CCI mice, while
being slightly weaker in the
ipsilateral part of the spinal cord in
CCI mice (Fig. 4B). The GTPcS
binding stimulated by dynorphin1–
13 was similar in naı¨ve mice (both
parts) and on the contralateral
part of the spinal cord in CCI
mice, but it was much weaker in
the ipsilateral part of the spinal
cord in CCI mice (Fig. 4C).
In the thalamus, the GTPcS
binding stimulated by the MOP
receptor selective peptide agonist
ligand DAMGO was similar in
naı¨ve mice (both parts) and the
ipsilateral part in CCI mice but
was much weaker on the
contralateral part of CCI mice
(Fig. 4D). The GTPcS binding
stimulated by Ile5,6deltorphin II
was very low but similar between
both parts of the thalamus in
naı¨ve mice and ipsilateral parts in
CCI mice, while signiﬁcantly
weaker stimulation was observedII and dynorphin1–13 in the spinal cord and
alamus
ntra Ipsi
1.1 ± 3.0 149.3 ± 3.2NS
6.7 ± 2.1 145.5 ± 1.5**
5.1 ± 1.7 126.1 ± 0.7NS
4.3 ± 2.9 125.9 ± 1.3*
8.4 ± 2.3 151.1 ± 2.8NS
6.5 ± 2.2 150.2 ± 1.8 **
s. NS: not signiﬁcant; *p< 0.05, **p< 0.01 and




































































Fig. 4. Opioid receptor signaling mediated by speciﬁc ligands in membranes prepared from spinal
cord and thalamus of naı¨ve and CCI mice in ipsi- and contralateral side. The maximal eﬃcacy (Emax)
above the basal activity of MOP, DOP and KOP receptors in stimulating G-proteins in the spinal cord
(A–C) and thalamus (D–F). Percent increases (%) in the speciﬁcally bound radiolabeled nucleotide
[35S]GTPcS are given above the basal (taken to be 100%) activity as a function of increasing
concentrations (1010–105 M) of DAMGO, Ile5,6deltorﬁn II and dynorphin1–13, a MOP, DOP and KOP
receptors ligand, respectively. Points represent mean value ± S.E.M. for three experiments
performed in triplicate. The level of basal activity indicates constitutive G-protein activity in the
absence of any stimulating ligand.
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7 September 2018only on the contralateral thalamus in CCI mice (Fig. 4E).
The GTPcS binding stimulated by dynorphin1–13 was
similar in naı¨ve mice (both parts) and in the ipsilateral
part in CCI-subjected mice, but it was weaker on the












The present study assessed neuropathic pain-related
behavioral changes accompanied by dynamic and
speciﬁc alterations of opioid system gene expression
levels and opioid receptor activity in the nociceptive
neuronal structures, the spinal cord and thalamus. In
the spinal cord, opioid peptide gene expression levels
increased in the parts ipsilateral to the site of the injury.
These changes were accompanied by tactile
hypersensitivity that was most pronounced on day 14.Please cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic
neuroscience.2018.08.013These increases in opioid peptide
gene expression may suggest the
enhancement of peptidergic
neuronal activity. Increase in the
synthesis of opioid prohormones
and the subsequent release of
endogenous ligands,
accompanied by a decrease in all
MOP, DOP, KOP opioid receptor
gene expression levels and
decreased functional activity of
these receptors, as examined by
GTPcS binding on day 14 (the
chosen time point, when the
strongest behavioral changes
were observed), in the ipsilateral
spinal cord and contralateral
thalamus in a mouse model of
neuropathic pain were
demonstrated. These results are
in agreement with other studies
that described signiﬁcantly
decreased density of MOP
receptor immunoreactivity in the
dorsal horn of the spinal cord in a
rat model of neuropathic pain
(Kohno et al., 1999; Zo¨llner et al.,
2003), suggesting a link to reduced
opioid analgesia.
The view is now accepted that
there is a loss in spinal opioid
responsiveness under neuropathy
(Cahill et al., 2003). It has been
shown that phosphorylated-MOP
receptor-like immunoreactivity is
increased on the ipsilateral side in
the superﬁcial laminae of the L5
lumbar spinal dorsal horn after sci-
atic nerve-ligation in mice; the
authors conclude that this, at least
in part, contributes to the reduction
in the antinociceptive eﬀect pro-
duced by morphine (Narita et al.,
2004). Other studies have shown
signiﬁcantly decreased density ofMOP receptor immunoreactivity in the dorsal horn of the
spinal cord in a rat model of neuropathic pain (Kohno
et al., 1999; Zo¨llner et al., 2003), suggesting a link to
reduced opioid analgesia. Opioids injected intrathecally
activate spinal pre- and postsynaptic opioid receptors, of
which 50 to 70% are presynaptically located on primary
aﬀerents (Gouarde`res et al., 1991; Abbadie et al.,
2002). Neuropathy induced by peripheral nerve injury
has been shown to cause profound reorganization of the
nociceptive circuits within the spinal cord and the brain,
including changes in gene expression and morphology
(Mayer et al., 1999; Ossipov et al., 2000; Przewlocki
and Przewlocka, 2001). However, the basis for the lack
of opioid eﬃcacy remains unclear. In 1999, Kohno et al.
indicated that nerve damage negatively inﬂuences the
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7 September 2018tic inhibition of excitatory postsynaptic currents, caused
normally by such agonists, is less eﬀective under nerve
injury conditions. The hyperexcitability of spinal neurons
with unilateral changes in opioid system activity is trans-
mitted to the thalamus under neuropathic conditions.
The ventral posterior thalamus is the major termination
site for the spinothalamic tract, and it relays nociceptive
activity to the somatosensory cortex. During neuropathic
pain, changes in neuronal ﬁring in characteristic groups
of neurons occur (Patel and Dickenson, 2016). Changes
in endogenous opioid system activity in this structure
may be very important for the ﬁnal feeling of pain.
In recent years, several papers have identiﬁed an
asymmetric distribution of opioid receptors and their
endogenous ligands after traumatic brain injury
(Bakalkin et al., 1982; Bakalkin and Kobylyansky, 1989;
Bakalkin, 1989; Hussain et al., 2012). Unilateral changes
in opioid receptor binding were also observed in chronic
pain patients with central post-stroke pain, which was
considered to reﬂect a sustained increase in the release
of endogenous opioids. In those patients, interhemi-
spheric comparisons using positron-emission tomography
demonstrated a signiﬁcant decrease in [11C]diprenorphine
binding in the posterior midbrain, medial thalamus and the
insular, temporal and prefrontal cortices contralateral to
the painful side (Maarrawi et al., 2007a,b). Our observa-
tion of MOP receptor changes in the spinal cord and tha-
lamus support and supplement the above information with
results in the animal model; furthermore, they extend this
clinical observation with information on changes in other
opioid receptors. In our study, KOP receptor mRNA levels
signiﬁcantly decreased on day 14 in the ipsilateral part of
the spinal cord and contralateral part of the thalamus.
Interestingly, the study of Xu et al. (2004) indicates that,
in contrast to our results, KOP immunoreactivity was
markedly increased in the L4-L5 spinal dorsal horn of
C57BL/6 mice 7–21 days after injury but not in mice pre-
treated with the KOP antagonist nor-binaltorphimine
(norBNI). On the other hand, in 2003, we showed
(Obara et al., 2003) that the administration of KOP recep-
tor antagonists norBNI and 50-guanidinonaltrindole (GNTI)
enhanced pain in rats and mice in a CCI model of neuro-
pathic pain. The hypersensitivity potentiation after norBNI
or GNTI administration was inhibited by the earlier admin-
istration of dynorphin antibody or ketamine. Our results
suggest that enhanced sensitivity is mediated through
non-opioid eﬀects of the endogenous opioid peptide,
dynorphin. The spinal release of PDYN-derived ligands
after nerve injury is known to contribute to neuropathic
pain development (Obara et al., 2003; Labombarda
et al., 2008; Mika et al., 2010; Chen et al., 2014;
Rojewska et al., 2014). Their non-opioid action is potenti-
ated by the blockade of KOP receptors; this ﬁnding corre-
sponds with the elevation of PDYN mRNA levels in the
ipsilateral part of the spinal cord in our experiments. In
addition, knock-out mice lacking PDYN, KOP, or G-
protein receptor kinase 3 did not show signiﬁcant
increases in KOP immunoreactivity after spinal nerve liga-
tion. KOP knock-out mice developed signiﬁcantly
increased tactile and thermal hypersensitivity in both the
early (ﬁrst week) and late (third week) intervals afterPlease cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic O
neuroscience.2018.08.013injury. It has been suggested that endogenous dynorphin
has both pronociceptive and antinociceptive actions after
nerve injury (Xu et al., 2004; Rojewska et al., 2014). The
dynorphin also acted as an endogenous agonist at KOP
receptors. Numerous studies have documented the
antinociceptive eﬀects of the intrathecal and systemic
administration of selective KOP agonists (Nakazawa
et al., 1991; Kolesnikov et al., 1996; Obara et al., 2003;
Rojewska et al., 2014). Thus, the endogenous opioids
derived from PDYN may have both antinociceptive and
pronociceptive actions. It is not clear how the sustained
activation of opioid receptors caused by endogenous
dynorphin contributes to the neuropathic pain state; as
the dynorphin level is higher in neuropathy than in physi-
ological conditions, it is probably that it may be able to
activate potentially pronociceptive receptors (such as
NMDA and bradykinin receptors) after the saturation of
KOP receptors (Vanderah et al., 1996; Obara et al.,
2003; Rojewska et al., 2014). Furthermore, KOP receptor
functional activity is weaker, as was shown in our study
with GTPcS binding. The lower functional activity of
KOP receptors might shift the balance from antinocicep-
tive to pronociceptive actions of the endogenous dynor-
phin system and thus contribute to the weakening of the
eﬀects of opioid drugs in neuropathic pain.
Changes in the DOP receptor mRNA expression show
lateralized and functional changes that diﬀered depending
on the structure. DOP receptor mRNA level decreased in
the ipsilateral part of the spinal cord on the 14th day, while
in the thalamus, a decrease was observed in the same
time point but only on the contralateral side. The
changes in functional activity measured by GTPcS
binding showed diﬀerences depending on the structure.
In the thalamus, a potent contralateral decrease in
expression was accompanied by a very dynamic
diﬀerence in functional GTPcS binding to DOP receptors
in a wide range of doses. The described strong
contralateral changes in the thalamic pain pathways,
occurring in all opioid receptors in both their expression
and GTPcS binding, may reduce the eﬀect of opioid
drugs in this kind of pain, but this aspect requires further
research.
In contrast, in the spinal cord, the signiﬁcant decrease
in the ipsilateral level of DOP receptor mRNA was
accompanied by a slight, much less pronounced than
for MOP and KOP, decrease in GTPcS binding to this
receptor. Interestingly, Obara et al. (2009) used an ED50
analysis to demonstrate that much higher doses of MOP
and KOP agonists injected intraplantarly are required to
produce analgesia in neuropathic versus inﬂammatory
pain; in contrast, the ED50 of DOP agonists is comparable
in both models of chronic pain. Many studies have shown
that selective DOP agonists do not lose their eﬀective-
ness in neuropathic pain (Mika et al., 2001, 2014;
Gave´riaux-Ruﬀ and Kieﬀer, 2011).
Our experiments show that changes in GTPcS binding
are similar between spinal and thalamic MOP/KOP
receptors, whereas the activation of DOP receptors is
remarkably diﬀerent in both structures studied. In the
spinal cord, the diﬀerence in opioid ligand stimulation of
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7 September 2018binding level on the contralateral side dropped
signiﬁcantly for a wide range of doses.
The spinal diﬀerences in GTPcS binding of MOP and
KOP receptors compared to DOP receptors are in
agreement with our previous behavioral studies. Mika
et al. (2014) showed that selective agonists of MOP and
KOP receptors (DAMGO and U50,488H, respectively),
in contrast to DOP receptor agonists (DPDPE, deltorphin
II or SNC80), lose their analgesic eﬀectiveness after
nerve injury. Our preliminary data performed in the CCI
model on mice on day 14 after injury indicate a lower
ED50 for morphine given i.th. in comparison to naive ani-
mals (1.25 g vs 2.9 g, respectively), while the ED50 for
enkephalin is very close to the values obtained in naive
mice (0.03 g vs 0.05 g, respectively). We suggest that this
diﬀerence may be related to the fact that DOP analgesia
is not dependent on injury-induced microglial activation.
Our in vitro study (Mika et al., 2014) conﬁrmed the pres-
ence of MOP/KOP receptors and the concurrent absence
of DOP receptors in microglial cells. This is in agreement
with other studies that have shown that microglia express
MOP and KOP receptors (Chang et al. 1996; El-Hage
et al. 2013; Merighi et al. 2013). Chao et al. (1996) ﬁrst
reported in 1996 that KOP receptors are present in
human microglia, and the expression was conﬁrmed by
the membrane binding of the selective ligand [3H]
U69,593. Thus, a slight change in GTPcS binding of
DOP ligands in the mouse CCI model in our studies
may explain this lack of change in the analgesic response
of these ligands after their spinal or peripheral administra-
tion compared to the attenuated MOP and KOP eﬃ-
ciency. However, in the thalamus, we demonstrated a
very strong reduction in the GTPcS binding of this recep-
tor. This change may be important in reducing the central
eﬀect of opioid drugs that have an MOP/DOP activity pro-
ﬁle. The functional state of the MOP receptor is known to
be dependent on the DOP receptor (Scherrer et al.,
2009), and the strong weakening of the binding of these
two receptors in the structures important for the central
eﬀects of opioid drugs can have a large impact on the
























Activity of opioid systems is altered by neuropathy
development, which induces an increase in endogenous
opioid peptide availability, which consequently results in
transiently enhanced opioid receptor occupancy leading
to a likely decrease in receptor expression. Our studies
provide evidence for selective changes in the activity of
spinal and thalamic opioid systems in a mouse
neuropathic pain model. Our experiments show that
similar changes in the GTPcS binding of MOP and KOP
receptors occurred in the spinal cord and thalamus,
whereas the binding to the DOP receptor was very
diﬀerent depending on the structure. At the spinal cord
level, the diﬀerence in ligand binding to the DOP
receptor was minimal which may explain the lack of
lower eﬃcacy of DOP receptor ligands after their i.th. or
i.pl. administration in neuropathic pain model. However,
strong reduction in the thalamic GTPcS binding may bePlease cite this article in press as: Rojewska E et al. Alterations in the Activity of Spinal and Thalamic O
neuroscience.2018.08.013the cause of reduced central eﬀect of opioid drugs with
MOP/DOP eﬃcacy in neuropathic pain.UNCITED REFERENCE
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